Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
Status: Forecasted
Posted date: October 1, 2024
Archive date: September 23, 2027
Close date: August 18, 2027
Opportunity ID: 356611
Opportunity number: PAR-24-294
Opportunity category: Discretionary
Agency name: National Institutes of Health
Agency code: HHS-NIH11
Award floor: $0
Award ceiling: $0
Cost sharing required: No
Funding Instrument Types
- Cooperative Agreement
Category of Funding Activity
- Education
- Environment
- Health
Eligible Applicants
- Small businesses
Categories (use these for quoted searches)
- agency_code:hhs_nih11
- category_of_funding_activity:education
- category_of_funding_activity:environment
- category_of_funding_activity:health
- cost_sharing_or_matching_requirement:false
- eligible_applicants:small_businesses
- funding_instrument_type:cooperative_agreement
- opportunity_category:discretionary
- status:forecasted
Reissue PAR-21-233 - The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.